MAR

• 1 Oct, 2024
  Spago Nanomedical i ny fas med fullt fokus på Tumorad-programmet
• 1 Oct, 2024
  Spago Nanomedical in new phase with full focus on the Tumorad program
• 15 Dec, 2023
  Spago Nanomedical rapporterar positiva topline-data från den kliniska fas 2a studien SPAGOPIX-02 i patienter med endometrios
• 15 Dec, 2023
  Spago Nanomedical reports positive top line data from clinical phase IIa study SPAGOPIX-02 in patients with endometriosis
• 7 Dec, 2023
  Första patienten doserad i Spago Nanomedicals kliniska fas I/IIa-studie inom Tumorad®-programmet
• 7 Dec, 2023
  First patient dosed in Spago Nanomedical’s clinical phase I/IIa study within the Tumorad® program
• 19 Oct, 2023
  Spago Nanomedical får klartecken att starta klinisk fas I/IIa-studie med Tumorad® i Australien
• 19 Oct, 2023
  Spago Nanomedical receives approval to initiate the clinical phase I/IIa study with Tumorad® in Australia
• 5 Oct, 2023
  Spago Nanomedical föreslår en fullt garanterad företrädesemission av units om cirka 30,6 MSEK för att avancera Tumorad
• 5 Oct, 2023
  Spago Nanomedical proposes a fully guaranteed rights issue of units of approximately SEK 30.6 million to advance Tumorad